Figure 2.

Illustration showing the study design and outcomes. (A) Study design and on‐label and off‐label devices for the treatment of severe aortic regurgitation. (B) The clinical outcomes of on‐label vs. off‐label devices at 30 days (left) and the 30 day mortality of new‐generation devices (NGDs), on‐label devices, off‐label devices, transfemoral access (TF), and transapical access (TA), respectively (right). The X axis indicates the occurrence of 30 day mortality. The Y axis represents the corresponding devices and procedural access. PPI, permanent pacemaker implantation; PVL, paravalvular leak.